Sterling Biotech
Sterling Biotech, headquartered in India, is a prominent player in the pharmaceutical and biotechnology industry, specialising in the production of high-quality pharmaceutical excipients and active pharmaceutical ingredients (APIs). Founded in 1995, the company has established a strong presence in both domestic and international markets, with significant operations across Asia, Europe, and the Americas. Renowned for its innovative approach, Sterling Biotech offers a diverse range of products, including starches, cellulose derivatives, and other excipients that enhance drug formulation. The company’s commitment to quality and sustainability has positioned it as a trusted partner for pharmaceutical manufacturers worldwide. With a focus on research and development, Sterling Biotech continues to achieve notable milestones, reinforcing its reputation as a leader in the biopharmaceutical sector.
DitchCarbon Score
How does Sterling Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sterling Biotech's score of 35 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sterling Biotech, headquartered in India, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Sterling Biotech Limited, which may influence its climate commitments and reporting practices. While Sterling Biotech has not established specific reduction targets or initiatives, it is important to note that emissions data and performance metrics may be cascaded from its parent company, Zydus Lifesciences Limited. This relationship suggests that any climate commitments or performance indicators may align with those of Zydus Lifesciences, although specific details are not provided. In the absence of direct emissions data or defined reduction initiatives, Sterling Biotech's climate strategy remains unclear. The company may benefit from adopting industry-standard climate terminology and practices to enhance its sustainability profile and align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 92,070,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 168,794,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sterling Biotech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
